Compositions and methods of inhibiting the binding of plasma igg autoantibodies to serotonin 2a receptor
AssigneeThe United States Government as represented by the Department of Veterans Affairs
InventorMARK B. ZIMERING
Life of this patent
Estimating the term…
Abstract
Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.
Claims20
A decoy peptide comprising or consisting of the sequence of QDDSKVFKEGSCLLADDN (SEQ ID NO:
- 1), or a fragment thereof.
-56. (canceled)
A method of treating a subject with a disease or disorder, the method comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a decoy peptide comprising or consisting of the sequence of QDDSKVFKEGSCLLADDN (SEQ ID NO:
- 1) or a fragment thereof and a pharmaceutically acceptable carrier, wherein the disease or disorder is a metabolic disease or disorder, neurologic disease or disorder, a cardiovascular or a microvascular disease or disorder, or a neurodegenerative disease or disorder.
A method of inducing sedation in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a decoy peptide comprising or consisting of the sequence of QDDSKVFKEGSCLLADDN (SEQ ID NO:
- 1) or a fragment thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.